public offering

Univest Securities closed a $16 million public offering for wire harness maker Linkers Industries, raising capital for acquisitions and operations.

LOBO Technologies prices $2M public offering of 3.9M units at $0.51 each, with proceeds for EV development and working capital.

Outlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions.

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.

Reviva Pharmaceuticals prices $10M offering at $1.50/share to fund brilaroxazine Phase 3 schizophrenia trial and operations.

SAB Biotherapeutics prices $85M offering at $3.85/share to fund Phase 2b trials of type 1 diabetes candidate SAB-142, with closing expected March 2026.

SAB Biotherapeutics prices $85M offering of shares and warrants to fund clinical trials for SAB-142, its lead type 1 diabetes candidate.

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.

Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.

Dianthus Therapeutics prices $625M upsized offering at $81/share to fund drug development and commercial readiness. Closing expected March 12, 2026.

Xenon Pharmaceuticals prices $650M upsized offering at $57/share with 10.5M shares. Proceeds fund pipeline acceleration; closes March 2026.

Kosmos Energy prices 97.5M share offering at $1.90/share for $185.25M gross proceeds, planning debt repayment.

Calidi Biotherapeutics closed a $6 million underwritten public offering, issuing 12.1 million shares and Series J, K, L warrants with $0.50 exercise prices.

REalloys Inc. ($ALOY) prices upsized $50M public offering at $18.50/share, with proceeds designated for working capital and general corporate purposes.

Calidi Biotherapeutics launches underwritten public offering of common stock and warrants, with Ladenburg Thalmann managing the raise for working capital and corporate purposes.

REalloys announces underwritten public stock offering with Clear Street, Needham & Company as lead managers to fund operations and general corporate needs.

MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/share, funding clinical trials and operations.

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.